Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A diffuse large B-cell lymphoma that is characterized by the expression of CD10, BCL-6, A-myb, and LMO2 genes, BCL-2 translocation, and c-REL amplification.
Biomarker and diagnostic research for diffuse large B-cell lymphoma germinal center B-cell type has been reported in the published literature.
8 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, procedural interventions, biologic therapy, and other interventions. Pipeline includes 4 PHASE2, 2 PHASE1, 1 EARLY_PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT03656835](https://clinicaltrials.gov/study/NCT03656835) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:49 AM UTC
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma |
NA |
Ohio State University Comprehensive Cancer Center |
ACTIVE_NOT_RECRUITING |
[NCT04799275](https://clinicaltrials.gov/study/NCT04799275) | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | PHASE2 | National Cancer Institute (NCI) | UNKNOWN |
[NCT06834373](https://clinicaltrials.gov/study/NCT06834373) | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | PHASE2 | Mayo Clinic | RECRUITING |
[NCT05627245](https://clinicaltrials.gov/study/NCT05627245) | Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | PHASE1 | National Cancer Institute (NCI) | ACTIVE_NOT_RECRUITING |
[NCT05755087](https://clinicaltrials.gov/study/NCT05755087) | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | PHASE1 | Lapo Alinari | UNKNOWN |
79 publications have been identified in PubMed for diffuse large B-cell lymphoma germinal center B-cell type. Kisho has analyzed 28 by research type. Research spans Case Report / Case Series (36%), Basic Science / Preclinical (29%), and Diagnostic / Biomarker (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 10 | 36% |
Laboratory research | 8 | 29% |
Testing and diagnosis research | 4 | 14% |
Disease patterns and progression | 3 | 11% |
Research summaries | 2 | 7% |
New treatment approaches | 1 | 4% |
Momose S (2026). [PMID: 41747827](https://pubmed.ncbi.nlm.nih.gov/41747827/). *Mod Pathol*. [Epidemiology / Natural History]
Arshad MS (2025). [PMID: 41377304](https://pubmed.ncbi.nlm.nih.gov/41377304/). *Ann Med Surg (Lond)*. [Case Report / Case Series]
Hansen-Abeck I (2025). [PMID: 41128869](https://pubmed.ncbi.nlm.nih.gov/41128869/). *Dermatologie (Heidelb)*. [Review / Meta-Analysis]
Tatterton DJ (2025). [PMID: 40896832](https://pubmed.ncbi.nlm.nih.gov/40896832/). *Blood*. [Epidemiology / Natural History]
Kaimi Y (2025). [PMID: 40523447](https://pubmed.ncbi.nlm.nih.gov/40523447/). *Hum Pathol*. [Basic Science / Preclinical]
Kubo T (2025). [PMID: 40301080](https://pubmed.ncbi.nlm.nih.gov/40301080/). *J Clin Exp Hematop*. [Case Report / Case Series]
Yanagisawa H (2025). [PMID: 39111885](https://pubmed.ncbi.nlm.nih.gov/39111885/). *Intern Med*. [Case Report / Case Series]
Tumuluru S (2025). [PMID: 39869833](https://pubmed.ncbi.nlm.nih.gov/39869833/). *Blood*. [Basic Science / Preclinical]
Kobayashi H (2025). [PMID: 40454408](https://pubmed.ncbi.nlm.nih.gov/40454408/). *Blood Neoplasia*. [Diagnostic / Biomarker]
Chrysikos D (2025). [PMID: 40656334](https://pubmed.ncbi.nlm.nih.gov/40656334/). *Cureus*. [Case Report / Case Series]